Steroids-dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders

Overview

Journal CNS Neurosci Ther

Specialties Neurology
Pharmacology

Date 2010 Jun 19

PMID 20557567

Citations 45

Authors

Maria Gabriela Sanchez

Melanie Bourque

Marc Morissette

Therese Di Paolo

Affiliations

Soon will be listed here.

Abstract

Introduction: Dopamine cell loss is well documented in Parkinson's disease and dopamine hypofunction is proposed in certain depressive states. At the opposite, dopamine hyperactivity is an enduring theory in schizophrenia with extensive supporting evidence.

Aims: This article reviews the sex differences in these diseases that are the object of many studies and meta-analyses and could be explained by genetic differences but also an effect of steroids in the brain. This article then focuses on the extensive literature reporting on the effect of estrogens in these diseases and effects of the other ovarian hormone progesterone as well as androgens that are less documented. Moreover, dehydroepiandrosterone, the precursor of estrogens and androgens, shows effects on brain dopamine neurotransmission that are reviewed. To investigate the mechanisms implicated in the human findings, animal studies are reviewed showing effects of estrogens, progesterone, and androgens on various markers of dopamine neurotransmission under intact as well as lesioned conditions.

Discussion: For possible future avenues for hormonal treatments in these central nervous system diseases, we discuss the effects of selective estrogen receptor modulators (SERMs), the various estrogen receptors and their specific drugs as well as progesterone drugs.

Conclusion: Clinical and experimental evidence supports a role of steroid-dopamine interactions in the pathophysiology of schizophrenia, depression and Parkinson's disease. Specific steroidal receptor agonists and SERMs are available for endocrine and cancer treatments and could find other applications as adjunct treatments in central nervous system diseases.

Citing Articles

Integrating network pharmacology with molecular docking and dynamics to uncover therapeutic targets and signaling mechanisms of vitamin D3 in Parkinson's disease.

Wang C, Wang Y, Xu Q Mol Divers. 2025; .

PMID: 39821175 DOI: 10.1007/s11030-024-11090-6.

Gonadal hormone abnormalities in young patients with first-episode schizophrenia.

Hu Q, Wang J, Liang J, Xiu M, Zhang S, Wu F Int J Neuropsychopharmacol. 2024; 27(12).

PMID: 39657134 PMC: 11656025. DOI: 10.1093/ijnp/pyae063.

Functional Food Nutrients, Redox Resilience Signaling and Neurosteroids for Brain Health.

Scuto M, Majzunova M, Torcitto G, Antonuzzo S, Rampulla F, Di Fatta E Int J Mol Sci. 2024; 25(22).

PMID: 39596221 PMC: 11594618. DOI: 10.3390/ijms252212155.

Early Effects of Alpha-Synuclein Depletion by Pan-Neuronal Inactivation of Encoding Gene on Electroencephalogram Coherence between Different Brain Regions in Mice.

Vorobyov V, Deev A, Morozova O, Oganesyan Z, Krayushkina A, Ivanova T Biomedicines. 2023; 11(12).

PMID: 38137503 PMC: 10741163. DOI: 10.3390/biomedicines11123282.

Antidepressant effects of novel positive allosteric modulators of Trk-receptor mediated signaling - a potential therapeutic concept?.

Madjid N, Lidell V, Nordvall G, Lindskog M, Ogren S, Forsell P Psychopharmacology (Berl). 2023; 240(8):1789-1804.

PMID: 37394539 PMC: 10349764. DOI: 10.1007/s00213-023-06410-x.

References

Anthony M, Williams J, Dunn B . What would be the properties of an ideal SERM?. Ann N Y Acad Sci. 2002; 949:261-78. DOI: 10.1111/j.1749-6632.2001.tb04031.x. View

Saunders-Pullman R, Parides M, Fahn S, Saunders H, Bressman S . The effect of estrogen replacement on early Parkinson's disease. Neurology. 1999; 52(7):1417-21. DOI: 10.1212/wnl.52.7.1417. View

Di Paolo T, Falardeau P . Modulation of brain and pituitary dopamine receptors by estrogens and prolactin. Prog Neuropsychopharmacol Biol Psychiatry. 1985; 9(5-6):473-80. DOI: 10.1016/0278-5846(85)90004-1. View

Erb J, Kadane J, TOURNEY G, Mickelsen R, Trader D, Szabo R . Discrimination between schizophrenic and control subjects by means of plasma dehydroepiandrosterone measurements. J Clin Endocrinol Metab. 1981; 52(2):181-6. DOI: 10.1210/jcem-52-2-181. View

Ashok P, Radhakrishnan K, Sridharan R, Mousa M . Epidemiology of Parkinson's disease in Benghazi, North-East Libya. Clin Neurol Neurosurg. 1986; 88(2):109-13. DOI: 10.1016/s0303-8467(86)80005-1. View

McDermott J, Liu B, Dluzen D . Sex differences and effects of estrogen on dopamine and DOPAC release from the striatum of male and female CD-1 mice. Exp Neurol. 1994; 125(2):306-11. DOI: 10.1006/exnr.1994.1034. View

Kulkarni J, de Castella A, Fitzgerald P, Gurvich C, Bailey M, Bartholomeusz C . Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry. 2008; 65(8):955-60. DOI: 10.1001/archpsyc.65.8.955. View

Thompson T, Moss R . Estrogen regulation of dopamine release in the nucleus accumbens: genomic- and nongenomic-mediated effects. J Neurochem. 1994; 62(5):1750-6. DOI: 10.1046/j.1471-4159.1994.62051750.x. View

Zhou W, Cunningham K, Thomas M . Estrogen regulation of gene expression in the brain: a possible mechanism altering the response to psychostimulants in female rats. Brain Res Mol Brain Res. 2002; 100(1-2):75-83. DOI: 10.1016/s0169-328x(02)00134-1. View

10.

Ganz P, Rowland J, Desmond K, Meyerowitz B, Wyatt G . Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol. 1998; 16(2):501-14. DOI: 10.1200/JCO.1998.16.2.501. View

11.

Lewis C, Dluzen D . Testosterone enhances dopamine depletion by methamphetamine in male, but not female, mice. Neurosci Lett. 2008; 448(1):130-3. DOI: 10.1016/j.neulet.2008.10.011. View

12.

McDermott J, Anderson L, Dluzen D . Tamoxifen alters dopamine output through direct actions upon superfused corpus striatal tissue fragments. Neurochem Int. 1998; 32(3):299-307. DOI: 10.1016/s0197-0186(97)00086-7. View

13.

Tsang K, Ho S, Lo S . Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology. 2000; 54(12):2292-8. DOI: 10.1212/wnl.54.12.2292. View

14.

Kessler R . Epidemiology of women and depression. J Affect Disord. 2003; 74(1):5-13. DOI: 10.1016/s0165-0327(02)00426-3. View

15.

Riecher-Rossler A, Hafner H . Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr Scand Suppl. 2001; (407):58-62. DOI: 10.1034/j.1600-0447.2000.00011.x. View

16.

DAstous M, Gajjar T, Dluzen D, Di Paolo T . Dopamine transporter as a marker of neuroprotection in methamphetamine-lesioned mice treated acutely with estradiol. Neuroendocrinology. 2004; 79(6):296-304. DOI: 10.1159/000079664. View

17.

Carrer H, Cambiasso M . Sexual differentiation of the brain: genes, estrogen, and neurotrophic factors. Cell Mol Neurobiol. 2003; 22(5-6):479-500. PMC: 11533755. DOI: 10.1023/a:1021825317546. View

18.

MacDonald A, Schulz S . What we know: findings that every theory of schizophrenia should explain. Schizophr Bull. 2009; 35(3):493-508. PMC: 2669587. DOI: 10.1093/schbul/sbp017. View

19.

Huber T, Borsutzky M, Schneider U, Emrich H . Psychotic disorders and gonadal function: evidence supporting the oestrogen hypothesis. Acta Psychiatr Scand. 2004; 109(4):269-74. DOI: 10.1046/j.1600-0447.2003.00251.x. View

20.

Le Saux M, Morissette M, Di Paolo T . ERbeta mediates the estradiol increase of D2 receptors in rat striatum and nucleus accumbens. Neuropharmacology. 2005; 50(4):451-7. DOI: 10.1016/j.neuropharm.2005.10.004. View